Fierce PharmaOpinion

Editor's Corner—For the first PD-1xVEGF's sake, Summit must submit to Big Pharma, stat

The detailed results from the HARMONi trial—the first global phase 3 data set for the world’s first PD-1xVEGF bispecific, ...
The Manila Times

Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab) plus LAZCLUZE® (lazertinib) could re-set survival expectations in first-line EGFR ...

Chemotherapy-free combination regimen has the potential to usher in new era for first-line treatment, with median overall survival projected to exceed four years, surpassing monotherapy TKI osimertini ...
FierceBiotech

BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. The biotech linked BNT327 to a median overall survival (OS) of 16.8 months in a Chinese phase 2 ...